These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 30478168)

  • 21. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration.
    Imberti R; Cusato M; Villani P; Carnevale L; Iotti GA; Langer M; Regazzi M
    Chest; 2010 Dec; 138(6):1333-9. PubMed ID: 20558557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.
    Roger C; Wallis SC; Louart B; Lefrant JY; Lipman J; Muller L; Roberts JA
    J Antimicrob Chemother; 2016 Jun; 71(6):1643-50. PubMed ID: 26957490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients.
    Athanassa ZE; Markantonis SL; Fousteri MZ; Myrianthefs PM; Boutzouka EG; Tsakris A; Baltopoulos GJ
    Intensive Care Med; 2012 Nov; 38(11):1779-86. PubMed ID: 22810779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Doripenem Treatment during Continuous Renal Replacement Therapy.
    Vossen MG; Wenisch JM; Maier-Salamon A; Fritsch A; Saria K; Zuba C; Jilch S; Lemmerer R; Unger M; Jaehde U; Jäger W; Thalhammer F
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1687-94. PubMed ID: 26711775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome analysis of colistin-treated burn center patients.
    Wilkinson RE; Hill DM; Hickerson WL
    Burns; 2017 Sep; 43(6):1244-1249. PubMed ID: 28410932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Steady-state pharmacokinetic and pharmacodynamic profiling of colistin in critically ill patients with multi-drug-resistant gram-negative bacterial infections, along with differences in clinical, microbiological and safety outcome.
    Ram K; Sheikh S; Bhati RK; Tripathi CD; Suri JC; Meshram GG
    Basic Clin Pharmacol Toxicol; 2021 Jan; 128(1):128-140. PubMed ID: 33245629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.
    Markou N; Markantonis SL; Dimitrakis E; Panidis D; Boutzouka E; Karatzas S; Rafailidis P; Apostolakos H; Baltopoulos G
    Clin Ther; 2008 Jan; 30(1):143-51. PubMed ID: 18343250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy.
    Menna P; Salvatorelli E; Mattei A; Cappiello D; Minotti G; Carassiti M
    Chemotherapy; 2018; 63(1):35-38. PubMed ID: 29334366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study.
    Dalfino L; Puntillo F; Mosca A; Monno R; Spada ML; Coppolecchia S; Miragliotta G; Bruno F; Brienza N
    Clin Infect Dis; 2012 Jun; 54(12):1720-6. PubMed ID: 22423120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of diluent volume of colistimethate sodium on aerosol characteristics and pharmacokinetics in ventilator-associated pneumonia caused by MDR bacteria.
    Bihan K; Zahr N; Becquemin MH; Lu X; Bertholon JF; Vezinet C; Arbelot C; Monsel A; Rouby JJ; Langeron O; Lu Q
    J Antimicrob Chemother; 2018 Jun; 73(6):1639-1646. PubMed ID: 29506194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.
    Landersdorfer CB; Nguyen TH; Lieu LT; Nguyen G; Bischof RJ; Meeusen EN; Li J; Nation RL; McIntosh MP
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dosing guidance for intravenous colistin in critically-ill patients.
    Nation RL; Garonzik SM; Thamlikitkul V; Giamarellos-Bourboulis EJ; Forrest A; Paterson DL; Li J; Silveira FP
    Clin Infect Dis; 2017 Mar; 64(5):565-571. PubMed ID: 28011614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing.
    Jitmuang A; Nation RL; Koomanachai P; Chen G; Lee HJ; Wasuwattakul S; Sritippayawan S; Li J; Thamlikitkul V; Landersdorfer CB
    J Antimicrob Chemother; 2015; 70(6):1804-11. PubMed ID: 25698772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration.
    Karvanen M; Plachouras D; Friberg LE; Paramythiotou E; Papadomichelakis E; Karaiskos I; Tsangaris I; Armaganidis A; Cars O; Giamarellou H
    Antimicrob Agents Chemother; 2013 Jan; 57(1):668-71. PubMed ID: 23147733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy.
    Kalaria S; Williford S; Guo D; Shu Y; Medlin C; Li M; Yeung SYA; Ali F; Jean W; Gopalakrishnan M; Heavner M
    Pharmacotherapy; 2021 Feb; 41(2):205-211. PubMed ID: 33438291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
    Awissi DK; Beauchamp A; Hébert E; Lavigne V; Munoz DL; Lebrun G; Savoie M; Fagnan M; Amyot J; Tétreault N; Robitaille R; Varin F; Lavallée C; Pichette V; Leblanc M
    Pharmacotherapy; 2015 Jun; 35(6):600-7. PubMed ID: 26095008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.
    Isla A; Gascón AR; Maynar J; Arzuaga A; Toral D; Pedraz JL
    Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
    Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
    Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients.
    Boisson M; Jacobs M; Grégoire N; Gobin P; Marchand S; Couet W; Mimoz O
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7331-9. PubMed ID: 25267660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria.
    Kristoffersson AN; Rognås V; Brill MJE; Dishon-Benattar Y; Durante-Mangoni E; Daitch V; Skiada A; Lellouche J; Nutman A; Kotsaki A; Andini R; Eliakim-Raz N; Bitterman R; Antoniadou A; Karlsson MO; Theuretzbacher U; Leibovici L; Daikos GL; Mouton JW; Carmeli Y; Paul M; Friberg LE
    Clin Microbiol Infect; 2020 Dec; 26(12):1644-1650. PubMed ID: 32213316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.